SV2B: A Promising Drug Target and Biomarker for Neuronal Communication

Target Name: SV2B

NCBI ID: G9899

SV2B

SV2B: A Promising Drug Target and Biomarker for Neuronal Communication

Introduction

Sv2B (Synaptic vesicle glycoprotein 2B) is a transmembrane protein that plays a critical role in synaptic vesicle recycling and neurotransmitter release in the central nervous system (CNS). It is expressed in various neural circuits, including the dopamine system, and has been implicated in various neurological disorders. While several studies have investigated the potential therapeutic benefits of SV2B, its exact role in neurotransmission and its potential as a drug target remain unclear. In this article, we will explore the biology and behavior of SV2B, as well as its potential as a drug target and biomarker.

The biology of SV2B

SV2B is a 21-kDa protein that is expressed in the brain and other nervous organs. It is a member of the glycoprotein family, which consists of proteins that are characterized by the presence of terminal glycans. SV2B has four known isoforms, which are different in their cytoplasmic region lengths and the presence or absence of different post-translational modifications (PTMs).

Functions and interactions

SV2B is involved in various intracellular signaling pathways, including the regulation of neurotransmitter release, synaptic vesicle recycling, and cell survival. It has been shown to interact with various intracellular signaling molecules, including cAMP, PKA, and CREB/CREB-1. SV2B has has also been shown to play a role in modulating the release of neurotransmitters, such as dopamine, serotonin, and endocannabinoids.

In addition to its role in neurotransmission, SV2B is also involved in the regulation of synaptic vesicle recycling. SV2B has been shown to interact with vesicle-associated protein (VAP), which is a protein that is involved in the recycling of synaptic vesicles. This The interaction between SV2B and VAP suggests that SV2B may play a role in regulating synaptic vesicle number and function.

Potential as a drug target

SV2B's involvement in intracellular signaling pathways and its role in synaptic vesicle recycling make it a potential drug target. Several studies have investigated the effects of drugs that bind to SV2B and have shown that these drugs can modulate its expression and function. For example, one study found that the neurotransmitter release of SV2B was modulated by the neurotransmitter agonist scher spindle voxel (Sp) in rat neurons. The authors found that the release of SV2B was increased in response to Sp and that this increase was blocked by the pre-synaptic terminal placebo administration (DMSO) and the neurotransmitter antagonist N-acetyltetrahydro-aspartate (N-Asp-Trk), suggesting that SV2B may be a drug target for neurotransmission disorders associated with dysfunctional synaptic vesicle recycling.

Another study found that the expression of SV2B was modulated by the neurotransmitter agonist ethyl-L-cAMP, which is a common signaling molecule in the regulation of intracellular signaling pathways. The authors found that the expression of SV2B was increased in response to ethyl-L -cAMP and that this increase was blocked by the inhibitor bicucatin (ICI)-2, suggesting that SV2B may be a drug target for the regulation of intracellular signaling pathways.

Biomarker potential

SV2B has also been as a potential biomarker for various neurological disorders. Several studies have shown that SV2B is involved in the regulation of synaptic vesicle recycling, which is a critical step in the investigated regulation of neurotransmission. For example, one study found that SV2B was involved in the regulation of the release of neurotransmitters, such as dopamine, in response to chronic

Protein Name: Synaptic Vesicle Glycoprotein 2B

Functions: Probably plays a role in the control of regulated secretion in neural and endocrine cells

The "SV2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SV2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets